Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

NCT06418477 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Monoclonal Gammopathy of Renal Significance

Interventions

DRUG: Dara-CyBorD

Sponsor

Peking University People's Hospital